CARDIOLOGS
1.9.2020 08:02:13 CEST | Business Wire | Press release
Cardiologs , a global leader in artificial intelligence (AI) cardiology diagnostics, today announced an exclusive distribution agreement in France with MicroPort CRM , for the reselling of its cloud analysis solution for Holter ECGs. MicroPort CRM is a worldwide leader in the conception and distribution of implementable devices for the treatment of heart rhythm disorders and the leader in France of Holter ECG monitoring devices and software. This agreement marks the official launch, at a large scale, of Cardiologs’ European business operations.
As a pioneer in AI-based healthcare, Cardiologs is the first company to obtain a CE mark for an AI-based medical device. Cardiologs’ medical-grade AI automatically identifies cardiac rhythm disorders with a high level of accuracy and in a timely manner, cutting diagnosis and analysis time in half. Thanks to its secure cloud solution, which General Data Protection Regulations (GDPR) compliant and “Hébergeur de Données de Santé” (HDS) certified, the analysis is available in real-time, from everywhere, by all professionals involved in a patient’s care, thus simplifying the logistics of ECG diagnostics.
Cardiologs is device-agnostic and can interpret data from a broad range of cardiac monitoring devices, a choice aligned with the evolution of health tech towards greater openness and interoperability. Already in use in several healthcare facilities, Cardiologs’ solution has been immediately endorsed by the medical staff, as Dr. Laurent Fiorina, rythmolog at Institut Cardiovasculaire de Paris-Sud (France) and medical expert at Cardiologs confirms, “Cardiologs’ solution enabled us to be more efficient and doubled our Holter analysis capacity. We are now capable of providing our patients with fast and accurate ECG analysis. The ease of use was a major reason for the team’s fast endorsement of this new ECG analysis device.”
Yann Fleureau, co-founder and CEO of Cardiologs, said, “We are extremely enthusiastic to partner with MicroPort CRM for the distribution of our unique technology in France. Its leading position in the Holter market combined with the expertise of its business teams, makes MicroPort CRM an ideal business partner to widely distribute Cardiologs’ solution to all the French cardiologists in hospitals as well as in outpatient medical offices.”
Benoît Clinchamps, President of MicroPort CRM, adds: “We are very happy to launch this partnership with Cardiologs which perfectly reflects MicroPort CRM’s strategy: to offer new unique and innovative services that enable healthcare facilities and cardiologists to optimize their time, resources and improve patient diagnostics.”
France Schwarz, Director of Marketing Europe at Cardiologs added, “This agreement confirms our solution’s attractiveness and marks the first phase of our European marketing strategy.”
About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 5 million ECG recordings and is supported by a number of clinical publications.
For more information: https://cardiologs.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005648/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom